Form 4 for LAB STANDARD BIOTOOLS INC.
Accepted 2024-04-09 00:00:00 ET · period of report 2024-04-08 · accession 0000950170-24-043103 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-04-09 | 2024-04-08 | LAB | Egholm Michael | Pres, CEO, Dir | F - Tax | $2.71 | -102.6K | 531.6K | -16% | -$277.9K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-04-08 | F | D | 102,564 | $2.71 | 531,592 | D | — | — | (F1) The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain performance-based restricted stock units ("RSUs") granted to the reporting person on April 11, 2023, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on April 5, 2024 upon the determination by the Board of Directors of the Issuer that certain of the performance-based conditions were met. |